Roche ( OTCQX:RHHBY) ( OTCQX:RHHBF) ( OTCPK:RHHVF) said that the European Commission has approved its oral cancer drug, ...

The European Commission has approved Swiss pharma giant Roche’s Itovebi (inavolisib), in combination with palbociclib ...

Roche’s oral PI3K inhibitor Itovebi (inavolisib) has been approved by the European Commission (EC) as part of a combination ...

USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, July 23, 2025 /CNW/ -- USA News Group News Commentary – Cancer ...

Vir Biotechnology has a strong cash position and is poised to generate definitive data in antivirals and oncology, making ...

Neha Anand, Analyst, Biopharma Intelligence Services, Citeline, explains how the approval of Embrelis marks a pivotal moment ...

The Swiss pharmaceutical giant Roche secured two significant regulatory victories, potentially strengthening its market position across key therapeutic areas. The European Commission granted ...

Q2 2025 has demonstrated the pharmaceutical industry’s continued momentum in developing transformative therapies across ...

Baystreet.ca News Commentary – More and more young women are getting diagnosed with cancer than ever before, causing many to sound the alarm about reduced funding for prevention ...

The global companion diagnostics market is set to surge from USD 7.03 Billion in 2024 to USD 22.83 Billion by 2034, driven by rising cancer prevalence and precision medicine advancements. Key trends ...